NTRA Q1 2025 Earnings
Reported May 8, 2025 at 4:15 PM ET · SEC Source
Q1 25 EPS
$-0.50
Q1 25 Revenue
$501.8M
vs S&P Since Q1 25
-4.3%
TRAILING MARKET
NTRA +23.4% vs S&P +27.7%
Market Reaction
Did NTRA Beat Earnings? Q1 2025 Results
Natera posted a convincing beat across both earnings and revenue in the first quarter of 2025, reporting a net loss of $0.50 per share against analyst expectations closer to a $0.59 loss, while revenue climbed 36.5% year-over-year to $501.83 million,… Read more Natera posted a convincing beat across both earnings and revenue in the first quarter of 2025, reporting a net loss of $0.50 per share against analyst expectations closer to a $0.59 loss, while revenue climbed 36.5% year-over-year to $501.83 million, well ahead of the roughly $460.85 million consensus. The primary engine behind that top-line strength was broad-based volume growth and average selling price improvements, with total tests processed rising 16.2% to approximately 855,100, led by a 46.1% surge in oncology testing to roughly 167,700 units. Gross margin expanded meaningfully to 63.1% from 56.7% a year ago, reflecting cost discipline and favorable cash collections on prior-period tests. Operating losses widened modestly to $79.18 million as R&D and SG&A spending accelerated to support new products and clinical trials. The company generated $44.50 million in operating cash flow and ended the quarter with approximately $991.60 million in cash and investments. Encouraged by the momentum, Natera raised its full-year 2025 revenue guidance to $1.94 billion to $2.02 billion, representing approximately 26% pro-forma growth, while maintaining gross margin guidance of 60% to 64%.
Key Takeaways
- • Total test volume growth of 16.2% YoY to approximately 855,100 tests
- • Oncology test volume growth of 46.1% YoY to approximately 167,700 tests
- • Clinical oncology units grew ~16,500 sequentially from Q4 2024, a record sequential quarter growth
- • Average selling price improvements
- • Cash collections exceeding initial revenue estimates driving true-ups
- • Continued progress in reducing cost of revenues per test
- • Strong performance across all product areas: women's health, organ health, and oncology
NTRA YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
NTRA Revenue by Segment
With YoY comparisons, source: SEC Filings
“We delivered another strong quarter, with volume growth across the business, including a record growth quarter for Signatera. Our progress reflects the strength of our technology and the breadth and quality of the clinical data. With multiple high-impact datasets reading out and trials underway, we believe we're in a strong position to help millions of patients in the future.”
— Steve Chapman, Q1 2025 Earnings Press Release
NTRA Earnings Trends
NTRA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NTRA EPS Trend
Earnings per share: estimate vs actual
NTRA Revenue Trend
Quarterly revenue: estimate vs actual
NTRA Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 FY | $-0.50 | — | — | $665.5M | +11.39% |
| FY Full Year | $-2.42 | $-1.52 | +37.16% | $2.31B | +3.04% |
| Q3 25 MISS | $-0.35 | $-0.64 | -80.74% | $592.2M | +15.04% |
| Q2 25 MISS | $-0.59 | $-0.74 | -24.54% | $546.6M | +14.63% |
| Q1 25 | — | $-0.50 | — | $501.8M | — |